Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Dr. Xufen Yu | Medicinal Chemistry | Associate Professor at Fudan University, China

Dr. Xufen Yu is an Associate Professor in the Department of Medicinal Chemistry at Fudan University’s School of Pharmacy. She specializes in drug discovery, chemical biology, and targeted protein degradation, particularly in cancer therapeutics. Before joining Fudan University, she was an Instructor and Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, where she contributed significantly to pharmacological sciences. Dr. Yu has also held postdoctoral positions at Purdue University and the University of Hawaii at Hilo. She holds a Ph.D. from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry. Her research has led to numerous high-impact publications in journals such as Journal of Medicinal Chemistry, Oncogene, and Nature Cancer. With extensive expertise in PROTAC-based therapeutics and epigenetic regulation, Dr. Yu continues to make significant contributions to the field of medicinal chemistry and targeted cancer therapy.

Professional Profile : 

Google Scholar

Orcid

Scopus  

Summary of Suitability for Award:

Dr. Xufen Yu is an exceptionally accomplished researcher in medicinal chemistry, with significant contributions to drug discovery, targeted protein degradation, and epigenetics. Her extensive academic background, including a Ph.D. from the Chinese Academy of Sciences and postdoctoral research at prestigious institutions such as Purdue University and the Icahn School of Medicine at Mount Sinai, demonstrates her expertise in chemical biology and small-molecule therapeutics. She has consistently advanced the field through high-impact publications, innovative research, and groundbreaking discoveries in PROTACs and DUBTACs, which have transformed targeted cancer therapy.  Given her outstanding achievements, innovative research, and contributions to medicinal chemistry, Dr. Xufen Yu is highly suitable for the “Best Researcher Award”. Her pioneering work in targeted protein degradation, combined with her international recognition and research excellence, makes her a strong candidate. Her research has not only advanced scientific knowledge but also holds significant promise for therapeutic applications, reinforcing her eligibility for this distinguished honor.

🎓Education:

Dr. Xufen Yu earned her Ph.D. in Organic Chemistry from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry, in 2011. Her doctoral research focused on synthetic organic chemistry and drug discovery. Prior to that, she completed her undergraduate studies at Anhui University, Hefei, China, earning a Bachelor’s degree in Chemistry in 2006. With a strong academic foundation, Dr. Yu developed expertise in medicinal chemistry, chemical biology, and targeted protein degradation. Her educational journey equipped her with extensive knowledge of molecular design, synthetic methodologies, and structure-activity relationship studies, laying the groundwork for her future contributions to pharmacological sciences. Her rigorous training in organic synthesis and chemical biology has driven her impactful research in developing novel therapeutics, particularly in targeted protein degradation and epigenetic regulation.

🏢Work Experience:

Dr. Xufen Yu has had a distinguished career in academia and research, with extensive postdoctoral and faculty experience. She is currently an Associate Professor in the Department of Medicinal Chemistry at Fudan University, Shanghai, China. Before joining Fudan, she was an Instructor in the Department of Pharmacological Science at the Icahn School of Medicine at Mount Sinai, New York (2021–2022), following a postdoctoral fellowship at the same institution from 2017 to 2020. She also worked as a postdoctoral fellow in Chemistry at Purdue University (2013–2014) and in Pharmaceutical Science at the University of Hawaii at Hilo (2011–2013). Through these roles, she has contributed significantly to medicinal chemistry, focusing on drug discovery, targeted protein degradation, and cancer therapeutics. Her work across multiple prestigious institutions reflects her expertise in interdisciplinary research, integrating chemistry and pharmacology to develop novel small-molecule therapeutics.

🏅Awards: 

Dr. Xufen Yu has been recognized for her outstanding contributions to medicinal chemistry and drug discovery. She has received multiple awards and research grants for her pioneering work in targeted protein degradation and epigenetics. Her innovative research has been acknowledged with prestigious fellowships and funding from institutions such as the National Institutes of Health (NIH) and the Chinese Academy of Sciences. Additionally, she has been honored for her significant publications in high-impact journals, receiving accolades for breakthrough studies on PROTACs and epigenetic regulators in cancer therapy. Her commitment to scientific excellence has led to invitations as a speaker at international conferences, where she has shared her expertise in medicinal chemistry. Dr. Yu’s contributions have been instrumental in advancing chemical biology and therapeutic discovery, making her a well-respected figure in her field.

🔬Research Focus:

Dr. Xufen Yu’s research focuses on the development of novel therapeutic strategies targeting disease-related proteins, particularly in cancer and metabolic disorders. Her expertise lies in targeted protein degradation, including the design and synthesis of PROTACs (Proteolysis Targeting Chimeras) and DUBTACs (Deubiquitinase Targeting Chimeras). She has explored epigenetic regulation in cancer therapy, investigating how small molecules can modulate oncogenic transcription factors and chromatin regulators. Her work also includes studying the role of ubiquitin-proteasome and autophagy systems in disease mechanisms, aiming to develop highly selective small-molecule therapeutics. Through interdisciplinary approaches combining medicinal chemistry, chemical biology, and pharmacology, she has contributed to advancing targeted cancer treatments. Dr. Yu’s research has led to the discovery of several potent and selective degraders for oncogenic proteins such as EZH2, WDR5, and USP7, paving the way for new treatment modalities in oncology.

Publication Top Notes:

Macrocyclic drugs and synthetic methodologies toward macrocycles
Authors: X Yu, D Sun
Citations: 276
Year: 2013

Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism
Authors: AJ Bott, J Shen, C Tonelli, L Zhan, N Sivaram, YP Jiang, X Yu, V Bhatt, …
Citations: 155
Year: 2019

Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders
Authors: M Cheng, X Yu, K Lu, L Xie, L Wang, F Meng, X Han, X Chen, J Liu, …
Citations: 151
Year: 2020

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Authors: J Wang, X Yu, W Gong, X Liu, KS Park, A Ma, YH Tsai, Y Shen, T Onikubo, …
Citations: 134
Year: 2022

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Authors: X Yu, D Li, J Kottur, Y Shen, HS Kim, KS Park, YH Tsai, W Gong, J Wang, …
Citations: 103
Year: 2021

Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders
Authors: Y Shen, G Gao, X Yu, H Kim, L Wang, L Xie, M Schwarz, X Chen, …
Citations: 84
Year: 2020

Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery
Authors: AM Chiarella, KV Butler, BE Gryder, D Lu, TA Wang, X Yu, S Pomella, …
Citations: 77
Year: 2020

Cationic Palladium Complex Catalyzed Diastereo-and Enantioselective Tandem Annulation of 2-Formylarylboronic Acids with Allenoates
Authors: X Yu, X Lu
Citations: 57
Year: 2009

AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B
Authors: J Xu, X Yu, TC Martin, A Bansal, K Cheung, A Lubin, E Stratikopoulos, …
Citations: 51
Year: 2021

Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders
Authors: X Yu, J Xu, L Xie, L Wang, Y Shen, KM Cahuzac, X Chen, J Liu …
Citations: 42
Year: 2021

Assist. Prof. Dr. Nitin Srivastava | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assist. Prof. Dr. Nitin Srivastava | Medicinal Chemistry | Best Researcher Award

Assist. Prof. Dr. Nitin Srivastava , Amity University Uttar Pradesh Lucknow Campus , India

Dr. Nitin Srivastava is a distinguished Assistant Professor (Senior-most Grade) in the Department of Chemistry at Amity University Uttar Pradesh, Lucknow Campus. With over 16 years of teaching and research experience, he specializes in diverse fields such as engineering chemistry, physical chemistry, and quantum chemistry. Dr. Srivastava is a prolific researcher, focusing on organosulfur compounds with significant biological applications, including anticancer and antimicrobial activities. His innovative work emphasizes cleaner, greener, and cost-effective synthetic methods. Dr. Srivastava is also an accomplished author, having penned the book Environment & We for UPSC aspirants. His academic journey, coupled with his dedication to sustainable chemistry, has earned him multiple accolades, including the Young Scientist Award and the CV Raman Prize.

Professional Profile

Orcid

Scopus  

Summary of Suitability for Award:

Dr. Nitin Srivastava is an exceptional candidate for the “Best Researcher Awards,” given his prolific contributions to chemical research, particularly in sustainable and medicinal organosulfur chemistry. With over 16 years of experience in academia and research, he has demonstrated excellence in teaching, mentoring, and groundbreaking studies. His innovative work on carbon disulfide-mediated synthesis of bioactive compounds has resulted in eco-friendly and cost-effective methods for producing trithio carbonates, rhodanine derivatives, and thioureas, all of which show significant anticancer, antimicrobial, and anti-plasmodial activities. Dr. Nitin Srivastava’s consistent academic output, focus on sustainability, and ability to translate research into real-world applications make him an exemplary candidate for the “Best Researcher Awards.” His groundbreaking methodologies and commitment to environmentally friendly chemical synthesis stand out as significant achievements that resonate with the award’s purpose of honoring excellence and innovation in research.

🎓Education:

Dr. Nitin Srivastava earned his Ph.D. in Chemistry from Amity University Uttar Pradesh, focusing on carbon disulfide-mediated synthesis of biologically potent organosulfur scaffolds. His research emphasized the development of cleaner and greener synthetic methods for compounds with significant biological applications. He holds an M.Sc. in Physical Chemistry from the University of Lucknow (2001), where he graduated with First Division. Additionally, he cleared the CSIR-UGC NET exam twice (Dec 2002 & June 2003), reflecting his strong academic foundation. Dr. Srivastava’s educational journey is marked by a passion for sustainability and innovation in chemical sciences, laying the groundwork for his impactful teaching and research career.

🏢Work Experience:

Dr. Nitin Srivastava has over 16 years of teaching and research experience at renowned institutions. Since 2008, he has served as an Assistant Professor in the Department of Chemistry at Amity University Uttar Pradesh, where he teaches courses like quantum chemistry, instrumental analysis, and environmental studies. He also worked as a Lecturer at National P.G. College, Lucknow (2005–2008), focusing on solid-state and physical chemistry. His contributions extend beyond teaching, with a strong emphasis on research in sustainable organosulfur chemistry. Dr. Srivastava’s extensive experience has positioned him as a key educator and researcher in his field, influencing both students and the scientific community.

🏅Awards: 

Dr. Nitin Srivastava has been recognized for his outstanding contributions to chemical sciences. He received the Young Scientist Award (2022) from the International Academy of Science and Research, Kolkata, acknowledging his pioneering work in sustainable chemistry. In 2023, he was awarded the prestigious CV Raman Prize by the Institute of Researchers, highlighting his innovative research on organosulfur compounds. These accolades reflect his dedication to advancing sustainable chemical practices and his impactful contributions to academia and research.

🔬Research Focus:

Dr. Nitin Srivastava specializes in organosulfur chemistry, developing greener and cost-effective synthetic methods for compounds like trithio carbonates, thioureas, and rhodanine derivatives. His research emphasizes sustainability, using phase transfer catalysts to create bioactive molecules with significant medicinal applications. These compounds have demonstrated anticancer activity against cell lines like HeLa and U87-MG and antimicrobial and anti-plasmodial properties. Dr. Srivastava’s work bridges the gap between sustainable chemistry and practical applications in medicine, agriculture, and industry, contributing to global efforts in creating environmentally friendly chemical processes.

Publication Top Notes:

Effect of dopant solubility and excess doping on the superconducting properties of doped Nb₃Sn prepared by field-assisted sintering technique
Authors: Srivastava, N., Matthews, G.A.B., Liu, J., Grovenor, C.R.M., Santra, S.
Year: 2024
Citations: 0

A Novel and Easy Synthesis of 1H-Tetrazoles employing p-Toluenesulfonyl azide
Authors: Vithal, R.A., Ram, K., Chundawat, N.S., Nitin, S., Pal, S.G.
Year: 2024
Citations: 0

Novel thiosemicarbazone based sensors for transition metals
Authors: Vithal, R.A., Kishore, R., Janardan, D.S., Srivastava, N., Singh, G.P.
Year: 2024
Citations: 0

Synthesis and anticancer screening of substituted (phenyl)-1-((naphthalen-5-yl)methylene)thiosemicarbazide against PC3 prostate cancer cells
Authors: Anisree, S., Shanmugavelan, P., Palanisamy, S., Kishore, R., Srivastava, N.
Year: 2024
Citations: 0

Production of fatty acids from distilled aromatic waste biomass using oleaginous yeast
Authors: Singh, S., Chaturvedi, S., Syed, N., Khare, S.K., Rout, P.K.
Year: 2024
Citations: 1

Terminal-substituted benzoxazole based Schiff-base Mesogens and their Cu(II) complexes: Synthesis and structural characterization
Authors: Dubey, R., Pandey, J., Srivastava, N.
Year: 2024
Citations: 0

A novel bulk (Nb,Zr,Pt)67Ti33 high-entropy alloy superconductor: synthesis and structure-property relationship
Authors: Srivastava, N., Santra, S.
Year: 2024
Citations: 0

Improved production of alkaline and solvent-stable proteases from a halotolerant Exiguobacterium isolate through heterologous expression
Authors: Srivastava, N., Shiburaj, S., Khare, S.K.
Year: 2024
Citations: 4

Microwave-Assisted Phase Transfer Catalytic Synthesis of Aryl Benzothiazole Derivatives and Their Anticancer Screening
Authors: Yadav, S., Kishore, R., Srivastava, N.
Year: 2024
Citations: 1

Cleaner, Greener Synthesis and Anticancer Screening of Asymmetrical Trithiocarbonates
Authors: Srivastava, N., Chaturvedi, D., Kishore, R., Kaur, M., Kalia, N.
Year: 2024
Citations: 0

 

 

 

 

 

Dr. Batoul Rostom | Medicinal Chemistry Award | Best Researcher Award

Published on by Chemistry Awards

Dr. Batoul Rostom | Medicinal Chemistry Award | Best Researcher Award

Dr. Batoul Rostom , INSERM-CRM , France

🎓 Dr. Batoul Rostom is a dedicated researcher in medicinal chemistry, currently a postdoctoral fellow at INSERM-Centre de Recherche en Myologie, Sorbonne University. She earned her Ph.D. in Medicinal Chemistry and Cancer Biology, where she focused on synthesizing novel cyclocoumarol derivatives with dual COX-2 inhibitory and anticancer properties. Dr. Rostom has a solid academic foundation in biochemistry and reproductive biology, with experience spanning bioinformatics, synthetic chemistry, and immunology. Her research addresses pressing issues in cancer therapeutics and autoimmune diseases. She has authored impactful publications, contributed to scientific conferences, and mentored students. Dr. Rostom’s work combines innovation with clinical relevance, aiming to bridge the gap between bench research and therapeutic applications.

Professional Profile:

Google Scholar 

Orcid 

Scopus 

Summary of Suitability for Award:

Dr. Batoul Rostom’s remarkable achievements, interdisciplinary expertise, and impactful research make her a deserving candidate for the “Best Researcher Award.” Her ability to translate complex scientific concepts into therapeutic applications reflects her commitment to advancing both knowledge and societal well-being. Dr. Batoul Rostom exemplifies the qualities of an outstanding researcher, with her innovative contributions to medicinal chemistry and cancer biology. Her groundbreaking work in synthesizing cyclocoumarol derivatives as dual COX-2 inhibitors with anticancer properties showcases her ability to address pressing global health challenges.  Dr. Rostom’s impressive academic journey, from her Ph.D. at HESAM University to her postdoctoral role at Sorbonne University, highlights her dedication to advancing science.

🎓Education:

Dr. Batoul Rostom has a strong academic foundation in medicinal chemistry, biochemistry, and reproductive biology. She earned her Ph.D. in Medicinal Chemistry and Cancer Biology from HESAM University in France, where she focused on synthesizing novel cyclocoumarol derivatives with dual COX-2 inhibitory and anticancer properties. Her master’s degree in Reproductive Biology and Medical Aids from Lebanese University  centered on the impact of smoking on TET gene expression in sperm cells, optimizing RNA extraction techniques. She holds a bachelor’s degree in General Biochemistry from Lebanese University, with comprehensive training in molecular biology and biochemistry. Her education integrates interdisciplinary skills, blending synthetic chemistry, molecular biology, and bioinformatics.

🏢Work Experience:

Dr. Batoul Rostom’s career spans diverse research roles. As a postdoctoral researcher at INSERM-Centre de Recherche en Myologie, Sorbonne University , she develops therapeutic strategies for autoimmune myositis and cancer. During her Ph.D. research at CNAM in France, she synthesized and tested innovative cyclocoumarol derivatives targeting COX-2 and cancer pathways.  She led a COVID-19 PCR diagnostic team at Al Hadi Clinic, Lebanon, managing high-pressure operations during the pandemic. She has served as a private tutor , mentoring students in molecular biology and biochemistry. Her master’s internship explored smoking’s effects on male fertility, showcasing her diverse expertise.

🏅Awards:

Dr. Rostom’s remarkable achievements have earned her significant recognition in the field of medicinal chemistry. She was nominated for the prestigious International Chemistry Scientist Award for her groundbreaking contributions. As an active member of the Société de Chimie Thérapeutique (SCT), her work in therapeutic compound design has been highly acknowledged. Her Ph.D. journey was supported by a competitive Scholarship Award, highlighting her academic excellence. Dr. Rostom also received the Top Oral Communication Award for her impactful presentations and the Young Research Fellow Distinction for her exceptional poster contributions at SCT’s events. These accolades underscore her innovation, dedication, and influence in advancing scientific research.

🔬Research Focus:

Dr. Rostom’s research spans medicinal chemistry, synthetic biology, and molecular biology. She specializes in designing novel cyclocoumarol derivatives, focusing on dual COX-2 inhibitors with anticancer properties. Her expertise extends to synthetic chemistry, developing compounds with pharmacological relevance. Molecular biology techniques, including RT-qPCR, ELISA, confocal microscopy, and cell culture, are central to her work. Her master’s research delved into reproductive biology, investigating smoking’s effects on male fertility. Presently, she focuses on autoimmune diseases, designing therapies for myositis while leveraging bioinformatics for in silico compound development. Her interdisciplinary approach aims to bridge laboratory research with clinical applications.

Publication Top Notes:

    • “Fishing antioxidant 4-hydroxycoumarin derivatives: synthesis, characterization, and in vitro assessments”
    • “Coumarins derivatives and inflammation: Review of their effects on the inflammatory signaling pathways”
      • Citations: 34 citations